JP2021127321A - Composition for endurance improvement - Google Patents

Abstract

To provide a technique relating to endurance.SOLUTION: The present disclosure provides a composition for glycogen storage promotion, endurance improvement, endurance support, and fatigue prevention, improvement or inhibition containing Bifidobacterium longum NITE BP-02621 and/or Bifidobacterium breve FERM BP-11175 as an active ingredient.SELECTED DRAWING: None

Description

The present technology relates to a composition for promoting glycogen storage, a composition for improving endurance, a composition for assisting endurance, a composition for preventing, improving or suppressing fatigue, and the like.

In recent years, in modern society with irregular life and stress, moderate exercise and sports are encouraged for prevention of lifestyle-related diseases, health promotion, stress relief, etc., regardless of age or sex.
For example, elderly people are recommended to maintain or improve the quality of activities of daily living, such as moderate exercise, moderate sports, and maintenance of activities of daily living. It is said that such physical activities are effective for the elderly in preventing sarcopenia (age-related muscle weakness), releasing stress, and preventing forgetfulness. In general, sarcopenia is a decrease in muscle mass, strength, and physical function due to aging.
In general, in sports and exercise, physical fitness, especially endurance, anti-fatigue, and fatigue recovery, are regarded as important.

For example, Patent Document 1 discloses a physical activity promoter containing lactobacillus gazelli as an active ingredient for the purpose of providing lactic acid bacteria that promote physical function.

Japanese Unexamined Patent Publication No. 2013-47192 JP-A-2015-590103 Japanese Unexamined Patent Publication No. 2005-289861

The present inventor considered that endurance is important when continuously performing sports, moderate exercise, daily activities, etc., and focused on endurance. Furthermore, as a result of diligent studies on endurance, the present inventor focused on glycogen, which is an energy source for activities, rather than the conventional promotion of metabolic function and increase in muscle mass (particularly slow muscle mass).
Therefore, the main purpose of this technology is to provide technology related to endurance.

Conventionally, as a technique related to the promotion of glycogen storage, Patent Document 2 describes the processing of plants of the genus Araliaceae, which can increase the amount of glycogen accumulated in muscles safely and easily without applying exercise load. A muscle glycogen accumulation promoter characterized by containing powder has been described. Patent Document 3 describes a composition used for promoting glycogen storage, which comprises milk whey protein as an active ingredient for the purpose of providing a composition for promoting glycogen storage.

As a result of diligent studies, the present inventor has found that Bifidobacterium genus Longum and / or Breve, particularly Bifidobacterium Longum NITE BP-02621 and / or Bifidobacterium Breve FERM BP-11175. The present invention has been completed by finding that it has an endurance improving action, an endurance assisting action, a glycogen storage promoting action, and the like. This technology is as follows.

The present technology provides a composition for promoting glycogen storage containing Bifidobacterium longum NITE BP-02621 and / or Bifidobacterium Breve FERM BP-11175 as an active ingredient.
The present technology provides an endurance-enhancing or endurance-assisting composition containing Bifidobacterium longum NITE BP-02621 and / or Bifidobacterium Breve FERM BP-11175 as an active ingredient. be.
The present technology provides a composition for preventing, ameliorating or suppressing fatigue, which comprises Bifidobacterium longum NITE BP-02621 and / or Bifidobacterium Breve FERM BP-11175 as an active ingredient. ..
The endurance is preferably the endurance of the muscle.
The composition is preferably a pharmaceutical composition.
The composition is preferably a food composition.

This technology can provide technology related to endurance. The effects described here are not necessarily limited, and may be any of the effects described in the present technology.

Hereinafter, suitable embodiments for carrying out the present technology will be described. It should be noted that the embodiments described below show an example of typical embodiments of the present technology, and the scope of the present technology is not narrowly interpreted by this. In this specification, the percentage is expressed by mass unless otherwise specified. Further, the upper limit value and the lower limit value of each numerical value range can be arbitrarily combined as desired.

The present technology is a composition containing Bifidobacterium longum and / or Bifidobacterium breve as an active ingredient, and more preferably, Bifidobacterium longum NITE BP-02621 and / or Bifidobacterium. It is a composition containing Umm-Breve FERM BP-11175 as an active ingredient.
The composition according to the present technology is a composition used for promoting glycogen storage, improving endurance, assisting endurance, or preventing, improving, suppressing fatigue, and the like. The composition can also be used for pharmaceuticals, foods and the like.

Examples of the Bifidobacterium genus bacterium used in this technique include Bifidobacterium longum subsp. Longum; Bifidobacterium breve, and the like. One or more selected from the group.

Among the Bifidobacterium spp., Bifidobacterium longum (more preferably Bifidobacterium longum subspecies longum) and / or Bifidobacterium breve have glycogen storage promoting action and endurance. It is more suitable from the viewpoint of the effect of this technology such as force improving action.

Bacteria belonging to the genus Bifidobacterium used in this technology include, for example, the following strains from the viewpoint of the effects of this technology such as glycogen storage promoting action and endurance support, and one species selected from the group consisting of these. Alternatively, two or more types are suitable. That is, as the Bifidobacterium genus bacterium used in the present technology, Bifidobacterium Longham NITE BP-02621 and / or Bifidobacterium Breve FERM BP-11175 are more suitable.

As the Bifidobacterium subspecies longum, for example, Bifidobacterium longum subspecies longum NITE BP-02621 (BB536) (deposit date January 26, 2018) is suitable.

As Bifidobacterium breve, for example, Bifidobacterium breve FERM BP-11175 (MCC1274; B3) (Deposit date August 25, 2009), Bifidobacterium breve NITE BP-02622 (Deposit date 2018) (January 26, 2014) (M-16V) and the like, and one or more selected from the group consisting of these is preferable.

More specifically, the Bifidobacterium Longum Subspecies Longum NITE BP-02621 (ATCC BAA-999; BB536) is the National Institute of Technology and Evaluation Patent Microorganisms Depositary Center (NPMD) (Address: An international deposit based on the Budapest Treaty was made on January 26, 2018 at NITE BP-02621 (Room 2-5-8 122, Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan 292-0818). be. Bifidobacterium longum NITE BP-02621 is the same bacterium as Bifidobacterium longum ATCC BAA-999, and this Bifidobacterium longum ATCC BAA-999 is the American Type Culture, a conservation agency in the United States. It has been deposited with the Collection (ATCC) (US, 20110 Manassas University Bacteria, Virginia, 10801) under the accession number ATCC BAA-999. The strain is available as a commercial product (BB536) from Morinaga Milk Industry Co., Ltd.

The Bifidobacterium Breve FERM BP-11175 (MCC1274; B-3) is the Patent Organism Depositary Center of the National Institute of Industrial Technology (currently the National Institute of Technology and Evaluation (NITE) Patent Organism Depositary Center (NITE). IPOD) (NITE-IPOD)) (Address: 2-5-8 Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan 292-0818, Room 122) was entrusted with the accession number FERM BP-11175 on August 25, 2009. The number is an international deposit based on the Budapest Treaty. The strain is available as a commercial product (B-3) from Morinaga Dairy Co., Ltd.

Strains with "NITE" in the accession number are the National Institute of Technology and Evaluation Patent Microorganisms Depositary Center (NPMD) (Address: Room 2-5-8 122, Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan 292-0818) ) Is an international depositary organization based on the Budapest Treaty, and is a strain deposited.
Strains with "FERM" in the accession number are the Patent Organism Depositary Center (currently the National Institute of Technology and Evaluation (NITE) Patent Organism Depositary Center (IPOD) (NITE-IPOD)). Address: 2-5-8 Kazusakamatari, Kisarazu City, Chiba Prefecture, Japan 292-0818) This strain was deposited at an international depositary organization based on the Budapest Treaty.

The strain specified by the strain name exemplified in the present technology is not limited to the strain itself that has been deposited or registered with a predetermined institution under the strain name (hereinafter, also referred to as "deposited strain" for convenience of explanation). Substantially equivalent strains (also referred to as "derivative strains" or "derivative strains") are also included. That is, for example, the above-mentioned Bifidobacterium longum subspecies longum NITE BP-02621 (ATCC BAA-999; BB536) has the accession number of NITE BP-02621, and the above-mentioned Bifidobacterium breve FERM BP-11175. (MCC1274; B-3) is the accession number of FERM BP-11175, and includes not only the shares themselves deposited at the depositary institution but also the shares substantially equivalent thereto.
Regarding the strain, "a strain substantially equivalent to the above-mentioned deposit strain" means a strain that belongs to the same species as the above-mentioned deposit strain and can improve the glycogen storage amount, endurance, etc., which are the effects of the present invention. .. The stock substantially equivalent to the deposited stock may be, for example, a derivative stock having the deposited stock as a parent stock. Derivative strains include strains bred from deposit stocks and strains naturally generated from deposit stocks.

Examples of substantially the same strain and derivative strain include the following strains.
(1) Strains determined to be the same strain by the RAPD method (Randomly Amplified Polymorphic DNA) and PFGE method (Pulsed-field gel electrophoresis) (described in Probiotics in food / Health and nutritional properties and guidelines for evaluation 85 Page 43)
(2) Strains that carry only genes derived from the deposited strain, do not have genes derived from foreign countries, and have a DNA identity of 95% or more (preferably 98% or more) (3) Strains bred from the strains Strains with the same trait (including genetically modified, mutated, spontaneous mutations)

Bacteria of the genus Bifidobacterium used in the present technology can be easily grown by culturing the bacterium. Further, as the Bifidobacterium genus bacterium used in the present technology, those obtained by appropriately producing can be used, and commercially available products can also be used.
The method for culturing the Bifidobacterium bacterium used in this technique is not particularly limited as long as the Bifidobacterium bacterium can grow, and the method usually used for culturing the Bifidobacterium bacterium is appropriately modified as necessary. Can be used. For example, the culture temperature may be 25 to 50 ° C, preferably 30 to 40 ° C. The culture is preferably carried out under anaerobic conditions, and for example, the culture can be carried out while aerating an anaerobic gas such as carbon dioxide.

The medium for culturing the Bifidobacterium genus bacterium is not particularly limited, and a medium usually used for culturing the Bifidobacterium genus bacterium can be appropriately modified and used as necessary. As the carbon source of the medium, for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolyzate, and waste sugar honey can be used depending on the assimilation property. As the nitrogen source of the medium, for example, ammonium salts such as ammonia, ammonium sulfate, ammonium chloride and ammonium nitrate and nitrates can be used. Further, as the inorganic salts of the medium, for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate and the like can be used. In addition, organic components such as peptone, soybean flour, defatted soybean meal, meat extract, and yeast extract may be used in the medium. Further, as the medium, a known medium may be prepared and used, and as the medium, for example, MRS medium can be preferably used as the prepared medium.

The morphology of the bacterium belonging to the genus Bifidobacterium used in the present technique is not particularly limited, and may be any of a bacterial cell, a culture of the bacterium, and a treated product of the bacterium.
The bacterial cell may be, for example, a live bacterial cell, a dead bacterial cell, or a mixture of a live bacterial cell and a dead bacterial cell, and the dead bacterial cell is a substance that has been sterilized, a cell wall or the like is destroyed, or the like. You may. Moreover, these bacterial cells may be either wet bacterial cells or dry bacterial cells. These cells are preferably live cells and / or dead cells from the viewpoint of the effects of the present technology such as glycogen storage promoting action and endurance improving action.

The bacterial culture may be used as it is containing the bacterial cells, diluted or concentrated, or the bacterial cells recovered from the culture may be used. The recovered bacterium may be a live bacterium or a dead bacterium, and may be both a live bacterium and a dead bacterium. As a bacterial culture, a culture supernatant or a culture fraction can also be used.
Bacterial treatments include those obtained by subjecting bacterial cells or cultures to various treatments such as heat treatment, crushing treatment, and drying treatment (for example, freeze-drying), and dilution of those treated products. Bacteria, freeze-dried products, or fractions can be used.

Bifidobacterium longum and / or Bifidobacterium breve, or the bacterial-containing composition in the present technology, promotes glycogen storage, improves endurance, and assists endurance. It also has an action of preventing, ameliorating or suppressing fatigue.
As used herein, "promoting glycogen storage" means that when the composition of the present technology is ingested, the glycogen content (g) per 1 g of muscle tissue or liver tissue is increased as compared with the case where it is not ingested. means.
As used herein, the term "endurance" means the ability to continuously perform physical activities (standing, walking, running, stair climbing, etc.) in sports and daily life.
In the present specification, "the action of assisting (supporting) endurance" means supplying an energy source to a tissue to prolong the sustainability (duration) of the activity ability (endurance) of the person or endurance. It means to maintain the improvement of.
In the present specification, "the action of assisting the endurance of a muscle" means supplying an energy source to a muscle to prolong the sustainability of the muscle activity of the person, improving the endurance of the muscle, and sustaining the endurance. It means to assist sexuality.
As used herein, the term "fatigue" means physical fatigue resulting from physical activity (standing, walking, running, climbing stairs, etc.) in sports and daily life.

In general, physical fitness, especially endurance, anti-fatigue, and fatigue recovery, are important when performing activities including exercise. Endurance limits and fatigue occur when glycogen in tissues is consumed and reaches below a certain level. For example, depletion of glycogen in tissues can lead to difficulties in maintaining activity.
It is generally known that there is a positive correlation between glycogen storage in tissues and endurance. Therefore, if the amount of glycogen stored in the tissue can be increased, it is considered to be useful for improving endurance, anti-fatigue, fatigue recovery, and assisting these.

It is also known that glycogen stored in muscle is consumed as glucose, while glycogen stored in the liver is converted to glucose and supplied to tissues of the whole body including muscle via blood. (Reference 1: Laurence Cole et al., Human Physiology, Biochemistry and Basic Medicine, 2015). By using Bifidobacterium longum and / or Bifidobacterium breve, as illustrated in the following examples, this technique has an effect of promoting glycogen storage not only in muscle tissue but also in liver tissue. From this, this technology can efficiently and stably supply the tissue to support (assist) endurance so as not to deplete glucose, which is an energy source required for the tissue, thereby improving endurance. It can be improved and sustained.

For this reason, this technology can be targeted for men and women of all ages, and is also beneficial for people who are prone to lack of exercise, especially for athletes and those who actively engage in exercise and sports. It is also beneficial.
Therefore, the Bifidobacterium longum and / or Bifidobacterium breve or the bacterium-containing composition in the present technology has an action of improving endurance, an action of sustaining endurance, and an action of assisting endurance. , Has the effect of preventing, improving, and suppressing fatigue.

This technology can sustain endurance in the activities of the person's daily life without applying a strong exercise load. For this reason, this technique is particularly useful for the elderly and those who perform rehabilitation because it is easy to avoid the risk of injury due to applying a strong exercise load.
Bifidobacterium longum and / or Bifidobacterium breve in this technique has an effect of improving muscle endurance, an effect of sustaining muscle endurance, an effect of assisting muscle endurance, and an effect of muscle fatigue. Has preventive, ameliorating, and inhibitory effects. Thus, this technique is more effective against muscle endurance and muscle fatigue.

The technique also provides glycogen storage in both muscle and liver tissue by ingesting Bifidobacterium longum and / or Bifidobacterium breve, even after intense exercise. The effect of increasing the amount can be obtained. Therefore, Bifidobacterium longum and / or Bifidobacterium breve in the present technology can be applied to those who desire recovery from fatigue (for example, those who are ill or after illness, those who are active or after activity). can.
Therefore, the Bifidobacterium longum and / or the Bifidobacterium breve in the present technology has an action of promoting recovery from fatigue of muscles and liver, an action of assisting recovery from fatigue, and the like.

The Bifidobacterium longum and / or Bifidobacterium breve of the present technology can use the bacterium itself as it is, or is a physiologically or pharmacologically acceptable conventional carrier or diluent. It can also be mixed and used together with.
In addition, the Bifidobacterium longum and / or Bifidobacterium breve of the present technology can be used for various uses such as pharmaceuticals, foods and feeds, and for various compositions.

In addition, this technology is used for the purposes of the above-mentioned effects of this technology, such as glycogen storage promotion, endurance improvement, endurance assistance, fatigue prevention, improvement, and suppression. Alternatively, Bifidobacterium breve or its use can be provided. In addition, Bifidobacterium longum and / or Bifidobacterium breve of this technology prevents, improves, and suppresses symptoms such as glycogen storage promotion method, endurance improvement method, endurance support method, and fatigue. It can be used as the active ingredient of the method.
In addition, the Bifidobacterium longum and / or Bifidobacterium breve of the present technology can be used for producing various formulations or compositions having the above-mentioned effects or intended for use.
In addition, Bifidobacterium longum and / or Bifidobacterium breve or the bacterium-containing composition of the present technology is used for glycogen storage promoting method, endurance improving method, endurance assisting method, or symptoms such as fatigue. It can be used for prevention, improvement, suppression or treatment.

In addition, the Bifidobacterium longum and / or Bifidobacterium breve of the present technology may be used for human or non-human animals (preferably primates) to which the present technology is applied, and humans and pets (dogs). , Cats, etc.), livestock (cattle, sheep, pigs, etc.) are preferable, and humans are more preferable.

In addition, the present technology may be used for therapeutic purposes or for non-therapeutic purposes.
"Non-therapeutic purpose" is a concept that does not include medical treatment, that is, treatment of the human body by treatment. For example, health promotion, prevention of lifestyle-related diseases (for example, reserve army in the boundary area) and the like can be mentioned.
"Prevention" means the prevention or delay of the onset of a disease or symptom, or the reduction of the risk of the disease or symptom to be applied.
"Amelioration" means improvement, prevention or delay of disease, symptom or condition, prevention or delay of deterioration, reversal of progression, prevention or delay.
"Suppression" means improvement, prevention or delay of disease, symptom or condition, prevention or delay of progression, reversal of progression, prevention or delay.

In the present technique, in addition to Bifidobacterium longum and / or Bifidobacterium breve, any component may be used in combination, if necessary. As an optional ingredient, an ingredient permitted in pharmaceuticals, foods, feeds and the like may be appropriately used. Examples of the optional component include sugars, sugar alcohols, polysaccharides, pH adjusters, fatty acid esters, flavoring and flavoring agents, fragrances, excipients and the like.

The compositions of the present technology can be produced by using Bifidobacterium longum and / or Bifidobacterium breve. In addition, the composition of the present technology can be obtained by mixing the Bifidobacterium genus bacterium with various raw materials of the composition so as to have the following predetermined content. In addition, the content or amount of various raw materials used in the composition of the present technology may be the same or similar amount with reference to the amount of various raw materials normally used in the target composition.
The composition of the present technology can be produced by using a known production method.

The method for producing the composition of the present technology will be described below, but the method for producing the composition of the present technology is not limited thereto. Thereby, a new composition can be provided, and examples of the use of the composition include promotion of glycogen storage, improvement of endurance, endurance assistance and recovery from fatigue.

In addition, in the production method of the present technology, it is preferable to produce a food composition, which means that the Bifidobacterium longum and / or the Bifidobacterium breve of the present technology is ingestible and safe. Since it is expensive, it is easy to handle at the manufacturing stage, it is easy to apply fermentation technology (preferably fermented milk technology), and raw materials such as milk components or assimilation components such as plant-based components are appropriately used as required. Because it can be used. In addition, the manufacturing method of this technology can also provide health-conscious food compositions, of which food compositions for promoting glycogen storage, improving endurance, assisting endurance, and recovering from fatigue. Is preferable.

The composition of the present technology may be fermented milk, and when the fermented milk of the present technology is produced, in the production process of the production method of the present technology, Bifidobacterium longum and / or Bifidobacterium. A fermentation step using a brave may be included, or a step of mixing fermented products produced on another line may be included.
In addition, since the composition obtained by the production method of the present technology contains Bifidobacterium longum and / or Bifidobacterium breve of the present technology, it is used as a food raw material for adding the effect of the present technology. It can be used for foods to which the effects of the present technology are added or for manufacturing methods thereof.

Further, depending on the form of the composition of the present technology (for example, tablets, drinks, capsules, tablets, etc.), the production method of the present technology may include a step for forming the form, whereby the present invention may be included. Compositions comprising the technique Bifidobacterium longum and / or Bifidobacterium breve can be in various forms. In this forming step, the Bifidobacterium spp. And excipients can be mixed to obtain a mixture, for example, in the case of tablets, the mixture is tableted; in the case of drinks, the mixture is placed in a container. In the case of capsules, the mixture is filled in capsules.

The method for producing the composition of the present technology will be described as the first embodiment and the second embodiment, but the composition is used for promoting glycogen storage, improving endurance, assisting endurance, and the like. The composition is not limited to the composition for recovery from fatigue.

The present technology is a method for producing a food composition, which comprises at least one of the following steps (a) and (b) as the production method of the first embodiment. :
(A) Steps of mixing Bifidobacterium longum and / or Bifidobacterium breve and prebiotics of the present technology; or (b) Bifidobacterium longum and / or bi of the present technology. The process of mixing fidobacterium breve and milk components;
Can be provided.
Further, in the mixing step (a), it is preferable to further mix the milk component.
The step of obtaining the culture (A) in the second embodiment can also be carried out in the first embodiment in order to obtain the Bifidobacterium spp. Used in the first embodiment. Further, the step (B) for obtaining the bacterial powder in the second embodiment can be appropriately performed in the first embodiment as well.

By the production method of the first embodiment of the present technology, a composition for promoting glycogen storage, a composition for improving endurance, etc., which can efficiently exert the effects of the present technology in terms of production efficiency such as cost and workability, can be obtained. Obtainable.

In addition, the present technology is a method for producing a food composition, which comprises the following steps (A) and (B) as the production method of the second embodiment, and the food composition promotes the above-mentioned glycogen storage. It is a composition related to this technology such as a composition for improving endurance and a composition for improving endurance. :
(A) A step of culturing Bifidobacterium longum and / or Bifidobacterium breve of the present technology in a medium to obtain a culture;
(B) A step of subjecting the culture to drying to obtain bacterial powder;
Can be provided. The drying is preferably freeze-drying.
The steps (A) and (B) can be carried out with reference to the above-mentioned method for culturing a bacterium belonging to the genus Bifidobacterium used in the present technology. For example, a milk component may be mixed with a medium for culturing, or fermented milk may be appropriately fermented to obtain fermented milk. In addition, lactic acid bacteria and / or other Bifidobacterium spp. May be optionally used for fermentation.
Further, as the manufacturing method of the second embodiment, the configuration overlapping with the first embodiment may be omitted as appropriate.

By the production method of the second embodiment of the present technology, a composition related to the present technology such as a composition for promoting glycogen storage and a composition for improving endurance, which can exert the effect of the present technology satisfactorily with high production efficiency, can be obtained. Obtainable. A food composition, a pharmaceutical composition, or a feed composition can be obtained by the production method of the second embodiment, and among them, a food composition such as fermented milk or bacterial powder can be obtained from the viewpoint of production efficiency. Is preferable.

The form of the culture containing the Bifidobacterium longum and / or Bifidobacterium breve is not particularly limited and may be either liquid or solid, but the form is a dry form (for example, fungus). Powders, dried cultures, etc.) are suitable from the viewpoint of easy handling during production and storage. In addition, examples of the culture include the cells themselves from which the culture solution has been separated and the culture containing the cells as described above.

The drying method is not particularly limited, but is limited to a freeze-drying method, a spray-drying method (spray-drying method), a retort sterilization method, a freeze-drying method, a UHT sterilization method, a pressure sterilization method, a high-pressure steam sterilization method, and a dry heat sterilization method. Distribution steam sterilization method, electromagnetic wave sterilization method, electron beam sterilization method, high frequency sterilization method, radiation sterilization method, ultraviolet sterilization method, ethylene oxide gas sterilization method, hydrogen peroxide gas plasma sterilization method, chemical sterilization method (alcohol sterilization method, formalin) Fixation method, electrolyzed water treatment method) and the like.

Further, the bacterial cells may be crushed, and the crushed product may be one in which live bacterial cells are crushed, one in which dead bacterial cells are crushed, or one in which heating or freeze-drying is performed after crushing.
Of these, from the viewpoint of increasing the viable cell rate, it is preferable to subject the culture to freeze-drying, and from the viewpoint of increasing the production efficiency, it is preferable to subject the culture to spray-drying.

Further, in the composition of the present technology, a component having a known or future probiotic effect or a component assisting the probiotic effect can be used as long as the effect of the present technology is not impaired. Here, in general, probiotics refer to bacteria that have a beneficial effect in the intestine. In general, substances that serve as a selective nutrient source for bacteria that have a beneficial effect in the intestine and promote their growth are called prebiotics.
When prebiotics are used or contained to promote the growth of Bifidobacterium longum and / or Bifidobacterium breve of the present technology, 1 to 1,000, per 100 parts by mass of cells. 000 parts by mass is preferable, and 10 to 10,000 parts by mass is more preferable.

As the prebiotics, for example, various proteins such as whey protein, casein protein, soybean protein, or pea protein (pea protein) or mixtures thereof, decomposition products; amino acids such as leucine, valine, isoleucine or glutamine; vitamin B6 or Vitamin C and other vitamins; creatin; citric acid; fish oil; or components such as isomaltooligosaccharide, galactooligosaccharide, xylooligosaccharide, soybean oligosaccharide, fructo-oligosaccharide, lactulose, oligosaccharide such as human milk oligosaccharide (HMO) Etc., and one kind or two or more kinds selected from the group consisting of these may be used.
In addition, the composition of the present technology can be produced by blending the prebiotic component with the bacterium of the present technology or a culture thereof.

The "human milk oligosaccharides" that can be used in this technology include 2'-fucosyl lactose, 3-fucosyl lactose, 2', 3-difucosyl lactose, lacto-N-triose II, lacto-N-tetraose, and lacto. -N-neotetraose, lactose-N-fucopentaose I, lactose-N-neofcopentaose, lactose-N-fucopentaose II, lactose-N-fucopentaose III, lactose-N-fucopentaose V, lacto-N-neofco Pentaose V, lacto-N-difucohexaose I, lacto-N-difucohexaose II, 6'-galactosyllactose, 3'-galactosyllactose, lacto-N-hexaose and lacto-N-neohexaose, etc. Neutral human milk oligosaccharides, 3'-sialyl lactose, 6'-sialyl lactose, 3-fucosyl-3'-sialyl lactose, disialyl-lacto-N-tetraose and other acidic human milk oligosaccharides can be used. One or more selected from the group may be used.

The ingestion (administration) amount of the composition of the present technology is appropriately selected depending on the age, gender, condition, other conditions, etc. of the ingestion (administration) target.
Regardless of the amount and duration of ingestion (administration), the composition of the present technology can be ingested (administered) once a day or in multiple divided doses.
The content or dose of the bacterial cells (live or dead cells) of Bifidobacterium longum and / or Bifidobacterium breve of the present technology is not particularly limited, but is preferable in the above composition. 1 × 10 ³ to 1 × 10 ¹² (CFU / g or CFU / mL), more preferably 1 × 10 ⁵ to 1 × 10 ¹¹ (CFU / g or CFU / mL), even more preferably 1 × 10 ⁷ to 1 × 10 ¹⁰ (CFU / g or CFU / mL). CFU indicates Colony forming unit. In the present specification, when the bacterial cell is a dead bacterial cell, "CFU" is replaced with "individual cell (cells)".
The content or dose of the cells may be the content of the cells of Bifidobacterium longum only or the content of the cells of Bifidobacterium breve only, or the total of both. It may be a quantity. These may usually be in the range of content when distributed as an oral composition.
The number of cells (CFU) of the bacterium depends on the number of colonies that appear after culturing an appropriately diluted suspension of the bacterium on a suitable agar medium, for example, a BCP-added plate count agar medium (manufactured by Eiken Chemical Co., Ltd.). Can be measured.

The daily dose of the bacterial cells of the genus Bifidobacterium (live or dead cells) of the present technology is not particularly limited, but is 1 × 10 ³ to 1 × 10 ¹² CFU / day. It is preferably 1 × 10 ⁵ to 1 × 10 ¹¹ CFU / day, and even more preferably 1 × 10 ⁷ to 1 × 10 ¹⁰ CFU / day.
The dose of the cells may be the dose of Bifidobacterium longum alone, the dose of Bifidobacterium breve alone, or the total amount of both.
The dose of the bacterial cells of the genus Bifidobacterium of the present technology is, for example, preferably in the range of 0.5 to 5 g / day, more preferably in the range of 1 to 4 g / day, and 2 to 3 g / day in adults. More preferred.

The administration time and administration interval of the present technology are not particularly limited, and may be once a day or may be divided into a plurality of times, but once a day is preferable because it is convenient and effective.
Since Bifidobacterium longum and / or Bifidobacterium breve of this technology is highly safe, it should be administered or ingested for the above-mentioned symptoms or diseases such as decreased glycogen storage, decreased endurance, and fatigue. Is possible. Further, from the viewpoint of prevention, it is preferable to administer or ingest this technique before symptoms or diseases caused by decreased glycogen storage, decreased endurance, fatigue, etc. are observed. It is preferable to administer or ingest the present technique one week before (more preferably two weeks before) exercise from the viewpoint of easily obtaining a preventive effect and a subsequent improving effect.
Further, in this technique, after symptoms such as decreased glycogen storage, decreased endurance, and fatigue are observed, long-term administration or ingestion is preferable from the viewpoint of effect, more preferably 2 weeks or more, still more preferable. Is preferably 4 weeks or more from the viewpoint that the improvement effect can be easily obtained.

[Pharmaceutical composition]
When Bifidobacterium longum and / or Bifidobacterium breve is used in a pharmaceutical composition or pharmaceutical use, the drug may be administered orally or parenterally, but acts on the oral administration and mucosa. Administration is preferred. Parenteral administration includes, for example, injection (blood, skin, muscle, etc.), rectal administration, inhalation, and the like. Dosage forms for oral administration include, for example, tablets, capsules, lozenges, syrups, granules, powders, ointments and the like.
The usage and dosage in the pharmaceutical composition of the present technology are as described above.

In addition to the Bifidobacterium longum and / or Bifidobacterium breve, components such as excipients, pH adjusters, colorants, and flavoring agents that are usually used in the formulation are used. Can be used. Furthermore, components having a preventive or therapeutic effect on diseases known or found in the future can be used in combination depending on the purpose.

Further, it can be appropriately formulated into a desired dosage form according to the administration method. For example, in the case of oral administration, it can be formulated into a solid preparation such as a powder, a granule, a tablet or a capsule; a liquid preparation such as a solution, a syrup, a suspension or an emulsion. In the case of parenteral administration, it can be formulated into a suppository, a spray, an ointment, a patch, an injection, or the like.

In addition, the formulation can be carried out by a known method as appropriate depending on the dosage form. At the time of formulation, only the bacterium belonging to the genus Bifidobacterium or each isolated / purified fraction may be formulated, or a pharmaceutical carrier may be blended as appropriate.

Further, as the pharmaceutical carrier, various organic or inorganic carriers can be used depending on the dosage form. Examples of the carrier in the case of a solid preparation include excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents and the like.

Examples of excipients include sugar derivatives such as lactose, sucrose, glucose, mannit, and sorbit; starch derivatives such as corn starch, horse bell starch, α-starch, dextrin, and carboxymethyl starch; crystalline cellulose, hydroxypropyl cellulose, and the like. Cellulous derivatives such as hydroxypropylmethyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium; gum arabic; dextran; purulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; carbonic acid Carbonate derivatives such as calcium; sulfate derivatives such as calcium sulfate can be mentioned.

Examples of the binder include gelatin; polyvinylpyrrolidone; macrogol and the like in addition to the above-mentioned excipients.

Examples of the disintegrant include, in addition to the above-mentioned excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, carboxymethyl starch sodium, and crosslinked polyvinylpyrrolidone.

Examples of the lubricant include talc; stearic acid; metal stearic acid salts such as calcium stearate and magnesium stearate; colloidal silica; waxes such as pea gum and gay wax; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid. Sodium carboxylic acid salts such as sodium benzoate; Sulfates such as sodium sulfate; Leucine; Lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; Be done.

Examples of the stabilizer include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; acetic acid anhydride; and sorbic acid.

Examples of the flavoring agent include sweeteners, acidulants, and flavors.
Examples of the carrier used in the case of a liquid preparation for oral administration include a solvent such as water, a flavoring and odorant, and the like.

[Food composition]
The present technology can provide a food composition containing Bifidobacterium longum and / or Bifidobacterium breve as an active ingredient. The food composition of the present technology also includes beverages. The food composition of the present technology can be applied to the above-mentioned applications for prevention and improvement of symptoms such as decreased glycogen storage, decreased endurance, and fatigue. For example, health foods, functional foods, etc. whose concept is to improve endurance and anti-fatigue.

Further, as a food composition according to the present technology, infant formula can be mentioned. Infant milk powder for infants from 0 to 12 months, follow-up milk for infants from 6 to 9 months and younger children (up to 3 years old), at birth Prepared milk powder for low-birth-weight babies weighing less than 2500 g (low-birth-weight babies), various therapeutic milks used to treat babies with pathological conditions such as milk allergy and lactose intolerance. Point to.

When Bifidobacterium longum and / or Bifidobacterium breve is used in foods for humans or animals, it can be prepared by adding it to known foods, or it can be newly mixed with food ingredients. It is also possible to produce various foods.
The method of use, the amount used, and the content of the present technology in the food composition are as described above.

The foods may be in the form of liquid, paste, solid, powder, etc., in addition to tablets, liquid foods, feeds (including those for pets), etc., for example, flour products, instant foods, processed agricultural products, processed marine products. Examples include products, processed livestock products, milk / dairy products, fats and oils, basic seasonings, complex seasonings / foods, frozen foods, confectionery, beverages, and other commercial products.

Examples of wheat flour products include bread crumbs, macaroni, spaghetti, noodles, cake mix, fried chicken flour, bread crumbs and the like.
Examples of instant foods include instant noodles, cup noodles, retort / cooked foods, canned foods, microwave foods, instant soups / stews, instant miso soup / soups, canned soups, freeze-dried foods, and other instant foods. Be done.
Examples of processed agricultural products include canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, cereals (processed grain products), and the like.
Examples of processed fishery products include canned fishery products, fish hams and sausages, fish paste products, fishery delicacies, and tsukudani.
Examples of processed livestock products include canned livestock and pastes, livestock ham and sausage.
Examples of dairy products include processed milk, milk drinks, yogurts, lactic acid bacteria drinks, cheese, ice creams, formula milk powders, creams, and other dairy products.
Examples of fats and oils include butter, margarines, vegetable oils and the like.
Examples of basic seasonings include soy sauce, miso, sauces, processed tomato seasonings, mirins, vinegars, etc., and examples of the complex seasonings / foods include cooking mixes, curry ingredients, sauces, and the like. Examples include dressings, mentsuyu, spices, and other complex seasonings.
Examples of frozen foods include raw material frozen foods, semi-cooked frozen foods, and cooked frozen foods.
Examples of confectioneries include caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery, and other confectionery.

Beverages include, for example, carbonated beverages, natural fruit juices, fruit juice beverages, refreshing beverages containing fruit juice, fruit meat beverages, fruit beverages containing fruit grains, vegetable beverages, soymilk, soymilk beverages, coffee beverages, tea beverages, powdered beverages, concentrated beverages. , Sports beverages, nutritional beverages, alcoholic beverages, other favorite beverages and the like.
Examples of commercially available foods other than the above include baby food, sprinkle, ochazuke seaweed and the like.

In addition, the foods defined by the present technology can also be provided and sold as foods labeled for health use.
The "display" act includes all acts for informing the consumer of the use, and if the expression can remind or analogize the use, the purpose of the display, the content of the display, and the display. Regardless of the object, medium, etc., all fall under the "display" act of this technology.

Further, it is preferable that the "display" is performed by an expression that allows the consumer to directly recognize the above-mentioned use. Specifically, the above-mentioned act of transferring, delivering, transferring or displaying for delivery, importing, advertising, price list or transaction documents related to the product or the packaging of the product related to the food. Examples include the act of describing the purpose of use and displaying or distributing it, or describing the above-mentioned use in the information containing these and providing it by an electromagnetic (Internet, etc.) method.

On the other hand, as the display content, it is preferable that the display is approved by the government or the like (for example, a display obtained based on various systems established by the government and performed in a manner based on such approval). In addition, it is preferable to attach such display contents to packaging, containers, catalogs, pamphlets, promotional materials such as POPs at sales sites, and other documents.

In addition, "labeling" includes health foods, functional foods, enteral nutrition foods, special purpose foods, health functional foods, specified health foods, nutritional functional foods, functionally labeled foods, non-medicinal products, etc. The display is also mentioned. Among these, in particular, labeling approved by the Consumer Affairs Agency, for example, a labeling approved by a food system for specified health use, a system similar to this, and the like can be mentioned. Examples of the latter include labeling as food for specified health use, labeling as conditional food for specified health use, labeling indicating that it affects the structure and function of the body, labeling for reducing the risk of illness, and the like. More specifically, the labeling as a food for specified health use (especially the labeling for health use) stipulated in the Health Promotion Law Enforcement Regulations (April 30, 2003, Ministry of Health, Labor and Welfare Ordinance No. 86) and this A similar display is a typical example.

Such indications include, for example, "for those who want to improve their endurance", "support for improving their endurance", "for those who want to have a body that is less tiring", "for recovery from fatigue", and "worried about physical fatigue". For those who become, "promote recovery from fatigue" and so on.

[Feed composition]
When Bifidobacterium longum and / or Bifidobacterium breve is used as feed, it can be prepared by adding it to a known feed or mixed with the feed material to produce a new feed. You can also do it.
The usage method, usage amount, and content in the feed composition of the present technology are as described above.

Examples of the raw material of the feed include cereals such as corn, wheat, barley, and rye; bran such as bran, wheat bran, rice bran, and defatted rice bran; production lees such as corn gluten meal and corn jam meal; defatted milk powder, Animal feeds such as whey, fish flour, and bone meal; yeasts such as beer yeast; mineral feeds such as calcium phosphate and calcium carbonate; fats and oils; amino acids; sugars and the like. Examples of the form of the feed include pet food (pet food and the like), livestock feed, fish feed and the like.

As described above, this technology can be used in a wide range of fields such as foods, food compositions, functional foods, pharmaceuticals, and feeds.

The present technology can also adopt the following configurations.
[1] A composition for promoting glycogen storage, which comprises Bifidobacterium longum and / or Bifidobacterium breve as an active ingredient among the bacteria of the genus Bifidobacterium. The glycogen storage promotion is preferably muscle glycogen storage promotion and / or liver glycogen storage promotion.
[2] A composition for improving endurance or assisting endurance, which contains Bifidobacterium longum and / or Bifidobacterium breve as active ingredients among the bacteria of the genus Bifidobacterium. The endurance is preferably the endurance of the muscle.
[3] A composition for preventing, ameliorating, and suppressing fatigue, which comprises Bifidobacterium longum and / or Bifidobacterium breve as an active ingredient among the bacteria of the genus Bifidobacterium. The fatigue is preferably muscle fatigue.
[4] Among the bacteria of the genus Bifidobacterium, a composition for maintaining endurance and a composition for promoting recovery from muscle fatigue, which contains Bifidobacterium longum and / or Bifidobacterium breve as active ingredients. A composition for assisting in recovery from fatigue.
[5] It is preferable that the composition according to any one of [1] to [4] is a pharmaceutical composition or a food composition. Moreover, it is preferable that the composition is a food, a beverage, or a supplement.
[6] It is preferable that the composition according to any one of [1] to [5] is an oral composition or an ingestion composition.

[7] A method for promoting glycogen storage; a method for improving endurance or assisting endurance, which administers Bifidobacterium longum and / or Bifidobacterium breve or a composition containing the same among the bacteria of the genus Bifidobacterium. Method; Prevention, improvement or suppression of fatigue; Endurance sustaining method; Promotion of muscle / liver fatigue recovery; Fatigue recovery assisting method.

[7] Glycogen storage promotion; endurance improvement or endurance assistance; endurance prevention, improvement or suppression; endurance persistence; promotion of muscle / liver fatigue recovery; fatigue recovery assistance; Bacteria of the genus Bacteria or its use. It may be used for non-therapeutic purposes.
[8] Composition for promoting glycogen storage; composition for improving endurance or assisting endurance; composition for preventing, improving or suppressing fatigue; composition for maintaining endurance; recovery from fatigue of muscles and liver Bifidobacterium longum and / or Bifidobacterium among the Bifidobacterium genus bacteria for producing a composition such as a composition for assisting fatigue recovery. Brave or its use. The composition is preferably for pharmaceuticals or foods, and may be for supplements.

[9] A method for producing a food composition, which comprises the following steps (A) to (B):
(A) A step of culturing Bifidobacterium longum and / or Bifidobacterium breve among Bifidobacterium spp. In a medium to obtain a fermented product;
(B) A step of subjecting the fermented product to freeze-drying or heat-drying to obtain bacterial powder.
The food composition is a composition for promoting glycogen storage; a composition for improving endurance or assisting endurance; for preventing, improving or suppressing fatigue; a composition for maintaining endurance; promoting recovery from fatigue of muscles and liver. One or more selected from compositions for assisting fatigue recovery and the like are suitable.

[10] Among the Bifidobacterium spp. In any one of the above [1] to [9], Bifidobacterium longum and / or Bifidobacterium breve are preferably viable cells. And / or dead bacteria.
[11] The Bifidobacterium longum and / or Bifidobacterium breve in any one of the above [1] to [10] is preferably Bifidobacterium longum subspecies longum. (Bifidobacterium longum subsp. Longum), one or more selected from the group consisting of Bifidobacterium breve.
[12] The Bifidobacterium genus bacterium in any one of the above [1] to [11] is preferably Bifidobacterium longum subspecies longum NITE BP-02621 (BB536) and /. Or Bifidobacterium breve FERM BP-11175 (B-3).

Hereinafter, the present technology will be described in more detail based on Examples and Test Examples. It should be noted that the examples and test examples described below show typical examples and test examples of the present technology, and the scope of the present technology is not narrowly interpreted by this.

[Sample preparation]
Bifidobacterium longum NITE BP-02621 (accession number NITE BP-02621 (BB536): hereinafter, may be simply referred to as "BB536"), and Bifidobacterium breve FERM BP-11175 (accession number FERM BP). -11175 (MCC1274): Hereinafter, it may be simply referred to as “B-3”), and the lyophilized powder of viable cells was diluted with physiological saline to a concentration of 1 × 10 ^ 9 CFU / mL. These strains are available from NITE-IPOD.
Each cell diluent was used as it was as a viable cell-containing solution without treatment. Each cell diluted solution was heat-treated at 90 ° C. for 30 minutes and used as a killed cell-containing solution.
Comparative sample (control): Saline (0.9 w / v% sodium chloride aqueous solution)
Test sample 1: B. Longum NITE BP-02621 (BB536) Viable Bacterial Cell-Containing Solution Test Sample 2: B.I. Longum NITE BP-02621 (BB536) killed cell-containing solution Test sample 3: B.I. Breve FERM BP-11175 (B-3) Viable Cell Containing Solution Test Sample 4: B.I. Breve FERM BP-11175 (B-3) killed cell-containing solution

[Animal test]
A 7-week-old C57BL / 6J mouse (Charles River Laboratories, Japan: 45 healthy mice) was used as an experimental animal. Each mouse was allowed to freely ingest Lab MR stock feed (manufactured by Northan Industries) and tap water. After acclimation for 1 week, the mice were divided into 5 groups (9 mice in 1 group; comparative sample group, test sample 1 to 4 group), and the comparative sample or test sample 1 to 4 was orally administered using an oral sonde. The dose of test samples 1 to 4 was 1 mL per animal, 1 × 10 ^ 9 CFU / day / animal, and the number and duration of administration was once a day for 4 weeks. The dose of the comparative sample was 1 mL per animal, and the number and duration of administration was once a day for 4 weeks as in the test sample group.

Three weeks after the start of administration of the test sample, all experimental animals were subjected to a limit mileage test using a treadmill. The running speed of the mouse was changed according to the program shown in Table 1, and the running distance until the running mouse touched the rear electrode three times within 5 seconds was defined as the limit running distance.

One hour after the final administration of the sample was completed, the muscles (plantaris muscles) and liver of each mouse were removed under sevoflurane anesthesia. Each tissue was cut out in a block shape (about 20 mg), and the weight of each was measured. The weighed tissue was measured according to the method described in Reference 2 (S Lo, et. Al., J Appl Physiol, 28 (2), 234-236. Determination of Glycogen in Small Tissue Samples). At that time, the amount of glycogen per 1 g of tissue was calculated by correcting with the measured weight.

Table 2 shows the limit mileage of each group. An increase in the limit mileage was confirmed in all the groups of the live cell administration group and the dead cell administration group of BB536, and the live cell administration group and the dead cell administration group of B-3 as compared with the comparative sample group. rice field.

Table 3 shows the amounts of glycogen in the muscles and liver of each group. In all the groups of BB536 live and dead cells, and B-3 live and dead cells, the amount of glycogen in muscle and liver was higher than that of the control group. An increase was confirmed.

From the results of this experiment, by administration of Bifidobacterium longum NITE BP-02621 (live and dead cells) and Bifidobacterium Breve FERM BP-11175 (live and dead). , Muscle and liver glycogen content was increased, and as a result, endurance was confirmed to be improved.
From this, Bacteria bifidobacteria (more preferably, B. longum and / or B. Brebe) have an excellent endurance improving effect, an excellent muscle glycogen storage promoting effect, and an excellent liver glycogen storage effect. It was revealed that it has a promoting effect.

Claims (6)

A composition for promoting glycogen storage containing Bifidobacterium longum NITE BP-02621 and / or Bifidobacterium Breve FERM BP-11175 as an active ingredient. A composition for improving endurance or assisting endurance, which comprises Bifidobacterium longum NITE BP-02621 and / or Bifidobacterium Breve FERM BP-11175 as an active ingredient. The composition according to claim 2, wherein the endurance is the endurance of a muscle. A composition for preventing, ameliorating or suppressing fatigue, which comprises Bifidobacterium longum NITE BP-02621 and / or Bifidobacterium Breve FERM BP-11175 as an active ingredient. The composition according to any one of claims 1 to 4, wherein the composition is a pharmaceutical composition. The composition according to any one of claims 1 to 4, wherein the composition is a food composition.